Dear Editor,

Since the first case of COVID-19 was reported in Wuhan, this new respiratory disease has evolved rapidly and been found in almost all the countries in the world. From our clinical experiences during managing COVID-19 patients, we observed an extremely high fatality rate in invasive ventilation (IV) patients which was astonishing and unexpected.

To validate our assumption, we collected and analyzed the data of 469 ICU COVID-19 patients who were hospitalized from February 2020 to the end of March in 13 ICUs in Wuhan. At the time of data collection, all of the patients were either discharged or deceased (Table [1](#Tab1){ref-type="table"}). Table 1Centers and study periodsCentersStudy periodNo. of casesHuoshenshan Hospital (2 ICUs)February 2 to March 31118Leishenshan Hospital (2 ICUs)February 23 to March 3141Guanggu Hospital (2 ICUs)February 21 to March 2540Taikang Hospital (2 ICUs)February 11 to March 2142Zhongfaxincheng Hospital (3 ICUs)February 8 to March 15147Wuhan Fifth Hospital (1 ICU)February 20 to March 3121Union Hospital (1 ICU)February 15 to March 3160

Clinical features, laboratory results on admission, and outcomes are shown in Table [2](#Tab2){ref-type="table"}. We found that the mortality rate in the IV group was 92%, compared to the other two groups (6.4% in the NV group, 40.8% in the NIV group). Furthermore, patients in the IV group developed a higher rate of severe comorbidities such as acute kidney injury (AKI) which required continuous renal replacement therapy (CRRT) (26.5%) compared to the NV (2.9%) and NIV (5.3%) groups. Moreover, 10 patients (8.8%) in the IV group received ECMO implementation. Table 2Clinical features, laboratory results on admission, and outcomes of the study patientsAll (*n* = 469)No ventilation (*n* = 204)Invasive ventilation (*n* = 113)Noninvasive ventilation (*n* = 152)*P*Age68 ± 1367 ± 1571 ± 1067 ± 130.030Sex0.034 Male266 (56.7)108 (52.9)76 (67.3)82 (53.9) Female203 (43.3)96 (47.1)37 (32.7)70 (46.1)Comorbidities, no. (%) Hypertension240 (51.4)99 (48.5)56 (49.6)85 (56.7)0.288 Diabetes110 (23.6)41 (20.1)28 (24.8)41 (27.3)0.268 Coronary artery disease84 (18.0)44 (21.6)20 (17.9)20 (13.3)0.137 Chronic obstructive lung disease52 (11.1)13 (6.4)8 (7.1)31 (20.7)\< 0.001 Chronic kidney disease42 (9.0)21 (10.3)8 (7.1)13 (8.7)0.623Laboratory results on admission White blood cell count, × 10^9^/L9.4 ± 6.06.9 ± 3.612.7 ± 8.010.2 ± 5.2\< 0.001 Neutrophil count, × 10^9^/L8.5 ± 9.25.7 ± 6.412.6 ± 11.98.6 ± 5.1\< 0.001 Lymphocyte count, × 10^9^/L0.9 ± 0.61.0 ± 0.50.7 ± 0.80.9 ± 0.60.002 NLR (neutrophil/lymphocyte ratio)13.1 ± 13.57.8 ± 9.321.3 ± 16.013.9 ± 13.0\< 0.001 Monocytes, count, × 10^9^/L0.5 ± 0.40.5 ± 0.60.5 ± 0.40.5 ± 0.30.947 Platelet count, × 10^9^/L214 ± 112225 ± 97180 ± 123223 ± 1180.001 C-reactive protein (mg/L)78.7 ± 83.647.0 ± 51.4116.1 ± 94.292.6 ± 93.8\< 0.001 Procalcitonin (ng/ml)1.9 ± 8.80.7 ± 4.72.8 ± 10.52.7 ± 10.90.078 ALT (U/L)47.1 ± 95.231.6 ± 30.280.8 ± 179.144.3 ± 40.9\< 0.001 AST (U/L)60.2 ± 227.031.2 ± 25.0110.7 ± 429.460.9 ± 138.30.019 Total bilirubin (μmol/L)14.7 ± 11.511.0 ± 5.718.1 ± 13.216.8 ± 14.1\< 0.001 Direct bilirubin (μmol/L)8.1 ± 7.55.0 ± 5.19.9 ± 9.210.6 ± 7.3\< 0.001 Albumin (g/L)32.0 ± 5.632.7 ± 4.630.1 ± 7.032.4 ± 5.4\< 0.001[d]{.smallcaps}-dimer (μg/mL)5.9 ± 11.93.1 ± 5.313.2 ± 20.54.5 ± 7.00.276 Glucose (mmol/L)8.7 ± 4.77.1 ± 3.310.3 ± 6.89.5 ± 3.9\< 0.001 Serum creatine (Scr) (μmol/L)128.3 ± 190.7124.5 ± 197.5119.2 ± 165.2140.2 ± 199.90.636 SOFA score on day 14.2 ± 3.12.2 ± 2.26.0 ± 3.05.5 ± 2.7\< 0.001Continuous renal replacement therapy (CRRT), no. (%)44 (9.4)6 (2.9)30 (26.5)8 (5.3)\< 0.001Extracorporeal membrane oxygenation (ECMO), no. (%)10 (3.1)0 (0.0)10 (8.8)0 (0.0)\< 0.001Length of hospital stay (days)20.4 ± 13.227.3 ± 14.717.9 ± 12.316.1 ± 9.6\< 0.001Mortality, no. (%)179 (38.2)13 (6.4)104 (92.0)62 (40.8)\< 0.001

The mean age in the IV group was 71, which was significantly higher than the other two groups (67 in both the NIV group and NV group, *P* = 0.03). There were no significant differences in comorbidities on admission except chronic obstructive pulmonary disease (COPD). Interestingly, there were even more cases of COPD in the NIV group (31, 20.7%) than in the IV group (8, 7.1%). This could be explained that physicians tend to avoid intubation in chronic lung disease patients due to concern of barotrauma and higher DNR/DNI ratio in those patients. From laboratory results, significantly higher white blood cell count, lower lymphocyte count and platelet count, and higher CRP, AST, ALT, and total bilirubin are presented in the IV group than the other two groups on admission. SOFA scores in the IV and NIV groups were also significantly higher than the NV group. There were no significant differences in Scr among these groups on admission though. We can tell from the data that the patients in the IV group were older with a higher rate of hyperinflammation status on admission compared to the other two groups. These factors may lead to the rapid progress of respiratory failure and fatal outcome eventually \[[@CR1]\].

Researchers worldwide also start to realize that IV may not improve the mortality in COVID-19 patients \[[@CR2], [@CR3]\]. We have to admit that some of the COVID-19 patients who developed progressive worsening respiratory distress were refractory to NIV. Intubation is inevitable in those cases. However, sometimes physicians can be rushed to intubation. It has been reported that intubation can be successfully avoided by HFNO \[[@CR4], [@CR5]\].

As we all know, IV can cause a lot of complications including hypotension, ventilator-related infection, volume imbalance, and sedation-related delirium. The decision of intubation mostly based on clinical judgments and varies from case to case. There is a notion that NIV causes wide-spread dispersion of aerosol thus increases the risk of transmission to healthcare workers. This could be one of the reasons that encourages physicians to choose IV over NIV among clinical decisions \[[@CR5]\].

In conclusion, from our data in Wuhan, COVID-19 patients who were invasively ventilated exhibited pessimistic outcomes. This suggests that early intubation may not help patients but instead, make things head towards the wrong direction. We should try to avoid IV and utilize NIV at the early stage of respiratory failure until IV is inevitable \[[@CR6]\]. It is time for physicians to rethink the threshold of intubation in COVID-19 management.

Covid-19

:   Coronavirus disease 2019

NV

:   No ventilation (nasal cannula oxygen)

NIV

:   Noninvasive ventilation (BiPAP, CPAP, or high-flow nasal oxygen)

IV

:   Invasive ventilation

HFNO

:   High-flow nasal oxygen
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